|
市場調査レポート
マイクロRNAによる診断・治療市場と癌の個別化医療市場：2009年
MicroRNA Diagnostics, Therapeutics, and Cancer Personalized Medicine 2009 Market Report
|
Abstract
This is the latest and most up-to-date Market Analysis Report from Select
Biosciences addressing MicroRNA Diagnostics, Therapeutics and Cancer
Personalized Medicine. The Cancer Personalized Medicine Marketplace Provides a
Paradigm for the development of MicroRNA Diagnostics and Therapeutics and this
Market Report brings together these Emerging Disciplines. This comprehensive
report provides a thorough discussion and analysis of the cancer personalized
medicine space and from both a technical as well as market-focused
perspective. Cancer Personalized Medicine represents the leading-edge of the
broader Personalized Medicine Marketplace and Select Biosciences maps the
qualitative and quantitative market trends and metrics in this report
(including market segmentation, market sizing, growth rates, revenue
projections broken-out by product areas, and market penetration of various
technologies in cancer personalized medicine). Analysis of the cancer
personalized medicine space through bottom-up analysis, via detailed market
surveys administered by Select Biosciences to a worldwide industry participant
pool, are presented in this report. Commercial and competitive landscape of
the emerging microRNA diagnostics/therapeutics marketplace are presented in
the context of the leading edge of this space - cancer.
Extensive Worldwide Technical and Market Analyses Presented in this Report:
- Technical aspects of the Broader Personalized Medicine Space as well as
Cancer Personalized Medicine
- Current products in the Cancer Personalized Medicine Space: Their
mechanisms of action, projected revenues, competitive position and
benchmarking, with emphasis on Breast Cancer Personalized Medicine
- Segmentation of the Broader Personalized Medicine Marketplace by
Therapeutic/Disease Area Addressed Currently
- Segmentation of the Cancer Personalized Medicine Market by Types of Cancer
Addressed Currently
- Results and Analyses from Select Biosciences recent worldwide market
surveys focusing upon the qualitative and quantitative trends in Cancer
Personalized Medicine. Areas of coverage include the market penetrance of
various technologies used industry-wide, distribution of the industry with
respect to types of biomarkers studied, penetrance of diagnostic platforms,
and drivers/challenges to market adoption
- MicroRNAs identified with association with specific diseases
- MicroRNA-based Personalized Medicine
- MicroRNA Diagnostics/Therapeutics Industry Trends and Milestones
- MicroRNA Diagnostics/Therapeutics Competitive Landscape
- More details of the scope of coverage of this industry report are found in
the Table of Contents (TOC) for the report - see below for link to
downloadable PDF of the TOC
Table of Contents
Chapter I . Executive Summary
- Scope
- Personalized Medicine Market Segmentation
- The Broader Personalized Medicine Industry Landscape: Selected Therapies,
Biomarkers, and Indications
- Personalized Medicine: Quantitative Market Metrics (market size, product
class projected revenues, growth rate)
Chapter II . Personalized Medicine: Technology Landscape
- Definition of Personalized Medicine
- Growth of Personalized Medicine
- Examples of Personalized Medicine in Clinical Practice together with
Details of Mechanism of Action in vivo
- Companion Diagnostics drive Companion Therapeutics Sales
- The US FDA is a Driver for Personalized Medicine Market Adoption
- Emerging Trends and Themes in Personalized Medicine
Chapter III . Cancer Personalized Medicine Market Landscape
- [a]. Coupled Diagnostics/Therapeutics for Cancer - The Market Landscape of
the Major Commercial Products
- [b]. Predictors of Clinical Outcome in Breast Cancer Commercialized
Multigene Predictors of Clinical Outcome for Breast Cancer
- [c]. Personalized Medicine in Other Cancers and the Landscape of the
Emerging Cancer Personalized Medicine Space FLT3 for Acute Myeloid Leukemia
(AML)
- [d]. Personalized Medicine in Oral Anticoagulant (warfarin) Therapy
- [e]. Cancer Personalized Medicine Worldwide Primary Market Survey Data
- Respondent Pool Characterization
- Segmentation based on Type of Areas in Personalized Medicine
- Cancer Personalized Medicine Market Segmentation
- Segmentation of the Broader Personalized Medicine Marketplace by
- Therapeutic/Disease Areas Addressed Currently
- Segmentation of the Cancer Personalized Medicine Space by Types of Cancer
- Focused upon Currently
- Market Segmentation by Types of Biomarkers Studied Currently
- Segmentation of the Personalized Medicine Marketplace by Study of
microRNAs, Epigenetic Changes
- Market Penetrance of Technologies Currently Utilized in Personalized
Medicine
- Current Penetrance of Various Diagnostic Platforms into Personalized
Medicine
- Personalized Medicine Tests: Drivers and Challenges in Market Adoption
Chapter IV. MicroRNA Diagnostics and Therapeutics: Technology and Market Landscape
- Current Status of the MicroRNA Marketplace
- MicroRNA Dysregulation is Associated/Linked with Disease Processes
(primarily cancer)
- MicroRNA Cancer Mapping
- MicroRNAs that are Associated with Human Cancers
- MicroRNAs Associated with Diseases Other than Cancer
- Developmental Pathways Regulated by MicroRNAs
- MicroRNAs Regulating Cancer-related Genes
- MicroRNA Polymorphisms
- Deployment of MicroRNAs as Diagnostics and Therapeutics: Market Analysis
- Emerging Market Participants: Selected MicroRNA Diagnostics and
- Therapeutics-focused Companies (Company Profiles: Areas of Focus, Business
Models)
- Industry Update: MicroRNA Therapeutics in Development
- Industry Update: Milestones of Note in the MicroRNA Diagnostics and
Therapeutics Space
Appendix I. Research Methodology
Appendix II. Regulatory Guidelines in Personalized Medicine
Appendix III. Drug Metabolism Drives Efficacy and Toxicity
|
